Turning Point Therapeutics, Inc.
(NASDAQ : TPTX)

( )
TPTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.53%170.200.7%$964.07m
ABBVAbbVie, Inc. 1.67%140.341.9%$841.79m
PFEPfizer Inc. 0.61%49.570.9%$830.12m
LLYEli Lilly & Co. 0.39%302.501.1%$749.11m
MRKMerck & Co., Inc. 1.24%88.490.7%$749.03m
BMYBristol-Myers Squibb Co. 2.33%73.801.0%$664.96m
SIGASIGA Technologies, Inc. -4.76%22.190.0%$393.19m
AZNAstraZeneca Plc -1.38%65.121.0%$376.21m
ALNYAlnylam Pharmaceuticals, Inc. 5.56%230.748.1%$254.69m
GSKGSK Plc -0.64%40.310.3%$216.46m
HZNPHorizon Therapeutics Plc 0.07%69.655.4%$197.93m
SGENSeagen Inc. 1.43%178.335.7%$191.45m
NVSNovartis AG 0.43%85.940.2%$174.13m
RGENRepligen Corp. 1.70%250.466.7%$158.40m
NVONovo Nordisk A/S -0.76%102.420.1%$151.74m

Company Profile

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.